Search

Your search keyword '"Currie, Sue L."' showing total 21 results
Start Over Author "Currie, Sue L."
21 results on '"Currie, Sue L."'

4. PIVOT-12: a phase III study of adjuvant bempegaldesleukin plus nivolumab in resected stage III/IV melanoma at high risk for recurrence

Author

Eggermont, Alexander Mm, Ascierto, Paolo A., Khushalani, Nikhil I., Schadendorf, Dirk, Boland, Genevieve, Weber, Jeffrey, Lewis, Karl D., Johnson, Daniel, Rivalland, Gareth, Khattak, Adnan, Majem, Margarita, Gogas, Helen, Long, Georgina V., Currie, Sue L., Chien, David, Tagliaferri, Mary A., Carlino, Matteo S., Diab, Adi, Eggermont, Alexander Mm, Ascierto, Paolo A., Khushalani, Nikhil I., Schadendorf, Dirk, Boland, Genevieve, Weber, Jeffrey, Lewis, Karl D., Johnson, Daniel, Rivalland, Gareth, Khattak, Adnan, Majem, Margarita, Gogas, Helen, Long, Georgina V., Currie, Sue L., Chien, David, Tagliaferri, Mary A., Carlino, Matteo S., and Diab, Adi

Abstract

Bempegaldesleukin (BEMPEG: NKTR-214) is an immunostimulatory IL-2 cytokine prodrug engineered to deliver a controlled, sustained and preferential IL-2 pathway signal. Nivolumab (NIVO), a PD-1 inhibitor, has been shown to prolong survival in patients with advanced melanoma and recurrence-free survival in the adjuvant setting. PIVOT-02 showed that BEMPEG plus NIVO was well-tolerated and demonstrated clinical activity as first-line therapy in metastatic melanoma. PIVOT-12 is a randomized, phase III, global, multicenter, open-label study comparing adjuvant therapy with BEMPEG plus NIVO versus NIVO alone in adult and adolescent patients with completely resected cutaneous stage III/IV melanoma at high risk of recurrence. The primary objective is to compare the efficacy, as measured by recurrence-free survival, of BEMPEG plus NIVO versus NIVO.

Published
2022

6. Bempegaldesleukin plus nivolumab in first-line renal cell carcinoma: results from the PIVOT-02 study

Author

Tannir, Nizar M, primary, Cho, Daniel C, additional, Diab, Adi, additional, Sznol, Mario, additional, Bilen, Mehmet A, additional, Balar, Arjun V, additional, Grignani, Giovanni, additional, Puente, Erika, additional, Tang, Lily, additional, Chien, David, additional, Hoch, Ute, additional, Choudhury, Arkopal, additional, Yu, Danni, additional, Currie, Sue L, additional, Tagliaferri, Mary A, additional, Zalevsky, Jonathan, additional, Siefker-Radtke, Arlene O, additional, and Hurwitz, Michael E, additional

Published
2022
Full Text
View/download PDF

7. PIVOT-12: a Phase III study of adjuvant bempegaldesleukin plus nivolumab in resected stage III/IV melanoma at high risk for recurrence

Author

Eggermont, Alexander M. M. Ascierto, Paolo A. Khushalani, I, Nikhil Schadendorf, Dirk Boland, Genevieve Weber, Jeffrey and Lewis, Karl D. Johnson, Daniel Rivalland, Gareth and Khattak, Adnan Majem, Margarita Gogas, Helen Long, V, Georgina Currie, Sue L. Chien, David Tagliaferri, Mary A. and Carlino, Matteo S. Diab, Adi

Abstract

Bempegaldesleukin (BEMPEG: NKTR-214) is an immunostimulatory IL-2 cytokine prodrug engineered to deliver a controlled, sustained and preferential IL-2 pathway signal. Nivolumab (NIVO), a PD-L1 inhibitor, has been shown to prolong survival in patients with advanced melanoma and recurrence-free survival in the adjuvant setting. PIVOT-02 showed that BEMPEG plus NIVO was well-tolerated and demonstrated clinical activity as first-line therapy in metastatic melanoma. PIVOT-12 is a randomized, Phase Ill, global, multicenter, open-label study comparing adjuvant therapy with BEMPEG plus NIVO versus NIVO alone in adult and adolescent patients with completely resected cutaneous stage III/IV melanoma at high risk of recurrence. The primary objective is to compare the efficacy, as measured by recurrence-free survival, of BEMPEG plus NIVO versus NIVO. Lay abstract: Following surgery, patients with advanced melanoma may require further treatment to reduce the likelihood of disease recurrence. Nivolumab (NIVO), a checkpoint inhibitor, reduces the risk of melanoma recurrence by enhancing the ability of the immune system to fight disease. Despite the availability of NIVO and other therapies, many patients with melanoma still experience disease recurrence after surgery. This article presents information on a clinical trial named PIVOT-12, which aims to assess the effectiveness of a new investigational drug called bempegaldesleukin that modifies the immune system and is given with NIVO to patients with stage III/IV melanoma following surgery. The main end point being measured is recurrence-free survival, which measures the time between a patient starting the study and the date of disease recurrence.

Published
2022

8. PIVOT-12: a phase III study of adjuvant bempegaldesleukin plus nivolumab in resected stage III/IV melanoma at high risk for recurrence

Author

Eggermont, Alexander MM, primary, Ascierto, Paolo A, additional, Khushalani, Nikhil I, additional, Schadendorf, Dirk, additional, Boland, Genevieve, additional, Weber, Jeffrey, additional, Lewis, Karl D, additional, Johnson, Daniel, additional, Rivalland, Gareth, additional, Khattak, Adnan, additional, Majem, Margarita, additional, Gogas, Helen, additional, Long, Georgina V, additional, Currie, Sue L, additional, Chien, David, additional, Tagliaferri, Mary A, additional, Carlino, Matteo S, additional, and Diab, Adi, additional

Published
2022
Full Text
View/download PDF

9. Bempegaldesleukin Plus Nivolumab in First-Line Metastatic Melanoma

Author

Diab, Adi, primary, Tykodi, Scott S., additional, Daniels, Gregory A., additional, Maio, Michele, additional, Curti, Brendan D., additional, Lewis, Karl D., additional, Jang, Sekwon, additional, Kalinka, Ewa, additional, Puzanov, Igor, additional, Spira, Alexander I., additional, Cho, Daniel C., additional, Guan, Shanhong, additional, Puente, Erika, additional, Nguyen, Tuan, additional, Hoch, Ute, additional, Currie, Sue L., additional, Lin, Wei, additional, Tagliaferri, Mary A., additional, Zalevsky, Jonathan, additional, Sznol, Mario, additional, and Hurwitz, Michael E., additional

Published
2021
Full Text
View/download PDF

13. Hepatitis C virus infection among prisoners in the California State correctional system

Author

Fox, Rena K., Currie, Sue L., Evans, Jennifer, Wright, Teresa L., Tobler, Leslie, Phelps, Bruce, Busch, Michael P., and Page-Shafer, Kimberly A.

Subjects
Prisoners -- Health aspects, Hepatitis C virus -- Diagnosis, Hepatitis C virus -- Patient outcomes, Hepatitis C virus -- Care and treatment, Health, Health care industry
Published
2005

21. A therapeutic HBV vaccine containing a checkpoint modifier enhances CD8+ T cell and antiviral responses.

Author

Hasanpourghadi M, Novikov M, Ambrose R, Chekaoui A, Newman D, Xiang Z, Luber AD, Currie SL, Zhou X, and Ertl HC

Subjects
Animals, Mice, Hepatitis B, Chronic immunology, Hepatitis B, Chronic therapy, Hepatitis B, Chronic virology, Female, Humans, Hepatitis B immunology, Hepatitis B prevention & control, Hepatitis B virology, Disease Models, Animal, Mice, Inbred C57BL, CD8-Positive T-Lymphocytes immunology, Hepatitis B Vaccines immunology, Hepatitis B Vaccines administration & dosage, Hepatitis B virus immunology, Hepatitis B virus genetics
Abstract

In patients who progress from acute hepatitis B virus (HBV) infection to a chronic HBV (CHB) infection, CD8+ T cells fail to eliminate the virus and become impaired. A functional cure of CHB likely requires CD8+ T cell responses different from those induced by the infection. Here we report preclinical immunogenicity and efficacy of an HBV therapeutic vaccine that includes herpes simplex virus (HSV) glycoprotein D (gD), a checkpoint modifier of early T cell activation, that augments CD8+ T cell responses. The vaccine is based on a chimpanzee adenovirus serotype 6 (AdC6) vector, called AdC6-gDHBV2, which targets conserved and highly immunogenic regions of the viral polymerase and core antigens fused to HSV gD. The vaccine was tested with and without gD in mice for immunogenicity, and in an AAV8-1.3HBV vector model of antiviral efficacy. The vaccine encoding the HBV antigens within gD stimulates potent and broad CD8+ T cell responses. In a surrogate model of HBV infection, a single intramuscular injection achieved pronounced and sustained declines of circulating HBV DNA copies and HBV surface antigen; both inversely correlated with HBV-specific CD8+ T cell frequencies in spleen and liver.

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results